Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Retrophin

DB:17R
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
17R
DB
$638M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Retrophin has significant price volatility in the past 3 months.
17R Share Price and Events
7 Day Returns
13%
DB:17R
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-
DB:17R
-13.2%
DE Biotechs
-20.9%
DE Market
17R Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Retrophin (17R) 13% 4.5% 15.8% - -15.9% -36.5%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • No trading data on 17R.
  • No trading data on 17R.
Price Volatility
17R
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Retrophin undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Retrophin to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Retrophin.

DB:17R Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:17R
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (33.7%))
1.338
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.34
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.338 * 5.44%)
6.89%

Discounted Cash Flow Calculation for DB:17R using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Retrophin is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:17R DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.89%)
2020 -80.36 Analyst x2 -75.18
2021 -130.19 Analyst x2 -113.95
2022 -87.10 Analyst x1 -71.32
2023 -43.70 Analyst x1 -33.48
2024 56.00 Analyst x1 40.14
2025 85.71 Est @ 53.06% 57.47
2026 117.44 Est @ 37.02% 73.68
2027 147.74 Est @ 25.8% 86.71
2028 174.25 Est @ 17.94% 95.68
2029 195.93 Est @ 12.44% 100.65
Present value of next 10 years cash flows $160.00
DB:17R DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $195.93 × (1 + -0.39%) ÷ (6.89% – -0.39%)
$2,681.79
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,681.79 ÷ (1 + 6.89%)10
$1,377.72
DB:17R Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $160.00 + $1,377.72
$1,537.72
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,537.72 / 43.12
$35.67
DB:17R Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:17R represents 0.93982x of NasdaqGM:RTRX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.93982x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 35.67 x 0.93982
€33.52
Value per share (EUR) From above. €33.52
Current discount Discount to share price of €13.90
= -1 x (€13.90 - €33.52) / €33.52
58.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Retrophin is available for.
Intrinsic value
>50%
Share price is €13.9 vs Future cash flow value of €33.52
Current Discount Checks
For Retrophin to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Retrophin's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Retrophin's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Retrophin's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Retrophin's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:17R PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.46
NasdaqGM:RTRX Share Price ** NasdaqGM (2020-04-03) in USD $14.79
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Retrophin.

DB:17R PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RTRX Share Price ÷ EPS (both in USD)

= 14.79 ÷ -3.46

-4.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Retrophin is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Retrophin is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Retrophin's expected growth come at a high price?
Raw Data
DB:17R PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
38.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Retrophin, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Retrophin's assets?
Raw Data
DB:17R PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.13
NasdaqGM:RTRX Share Price * NasdaqGM (2020-04-03) in USD $14.79
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:17R PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RTRX Share Price ÷ Book Value per Share (both in USD)

= 14.79 ÷ 5.13

2.88x

* Primary Listing of Retrophin.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Retrophin is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Retrophin's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Retrophin has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Retrophin expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Retrophin expected to grow at an attractive rate?
  • Retrophin's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Retrophin's earnings growth is expected to exceed the Germany market average.
  • Retrophin's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:17R Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:17R Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 38.6%
DB:17R Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 25.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:17R Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:17R Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 497 62 83 2
2023-12-31 421 49 -5 3
2022-12-31 275 -38 -106 3
2021-12-31 204 -98 -123 6
2020-12-31 186 -64 -122 6
2020-04-05
DB:17R Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 175 -58 -146
2019-09-30 172 -57 -124
2019-06-30 169 -47 -142
2019-03-31 165 -31 -125
2018-12-31 164 -25 -103
2018-09-30 163 -22 -113
2018-06-30 162 -12 -76
2018-03-31 160 -4 -67
2017-12-31 155 7 -60
2017-09-30 150 0 -51
2017-06-30 144 -2 -70
2017-03-31 138 -3 -70

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Retrophin's earnings are expected to grow significantly at over 20% yearly.
  • Retrophin's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:17R Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Retrophin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:17R Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.30 1.92 0.67 2.00
2023-12-31 0.04 1.58 -1.46 3.00
2022-12-31 -2.09 -1.10 -2.79 3.00
2021-12-31 -2.62 -1.36 -3.77 6.00
2020-12-31 -2.72 -2.41 -3.30 7.00
2020-04-05
DB:17R Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.46
2019-09-30 -2.95
2019-06-30 -3.42
2019-03-31 -3.07
2018-12-31 -2.54
2018-09-30 -2.81
2018-06-30 -1.94
2018-03-31 -1.71
2017-12-31 -1.54
2017-09-30 -1.33
2017-06-30 -1.84
2017-03-31 -1.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Retrophin will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Retrophin's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Retrophin has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Retrophin performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Retrophin's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Retrophin does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Retrophin's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Retrophin's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Retrophin's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Retrophin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:17R Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 175.34 -146.43 128.95 140.96
2019-09-30 172.42 -123.62 127.40 136.81
2019-06-30 168.75 -141.65 123.73 136.04
2019-03-31 165.38 -125.28 109.86 132.56
2018-12-31 164.25 -102.68 103.65 123.76
2018-09-30 162.65 -112.84 104.33 111.12
2018-06-30 162.29 -76.12 100.95 96.92
2018-03-31 159.75 -67.02 104.69 81.94
2017-12-31 154.94 -59.73 101.33 78.17
2017-09-30 150.09 -50.72 100.91 78.66
2017-06-30 143.69 -70.04 101.56 78.82
2017-03-31 138.20 -70.21 95.93 77.01
2016-12-31 133.59 -47.90 91.94 70.82
2016-09-30 126.71 -41.77 88.40 66.21
2016-06-30 120.77 100.92 87.32 61.86
2016-03-31 111.53 88.80 83.81 54.75
2015-12-31 99.89 117.24 79.54 50.43
2015-09-30 83.53 90.68 68.50 49.87
2015-06-30 63.87 -32.88 63.57 48.45
2015-03-31 45.55 4.45 53.45 51.20
2014-12-31 28.20 -110.94 59.35 47.80
2014-09-30 14.12 -94.50 48.87 37.87
2014-06-30 5.77 -88.76 35.78 26.62
2014-03-31 0.03 -105.49 31.11 13.87
2013-12-31 -34.63 17.69 7.08
2013-09-30 -35.56 24.04 2.49
2013-06-30 -31.80 27.93 1.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Retrophin has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Retrophin has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Retrophin improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Retrophin's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Retrophin has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Retrophin's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Retrophin's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Retrophin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Retrophin's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Retrophin's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Retrophin Company Filings, last reported 3 months ago.

DB:17R Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 221.20 204.86 398.52
2019-09-30 245.96 202.36 407.02
2019-06-30 277.09 199.89 425.90
2019-03-31 285.71 220.01 447.65
2018-12-31 318.25 217.55 471.54
2018-09-30 319.07 215.13 478.81
2018-06-30 287.99 45.40 255.69
2018-03-31 299.48 45.24 264.06
2017-12-31 293.13 45.08 300.63
2017-09-30 304.52 44.91 303.87
2017-06-30 295.83 44.75 295.98
2017-03-31 300.94 44.58 248.16
2016-12-31 307.77 44.42 255.87
2016-09-30 307.60 44.26 274.30
2016-06-30 314.37 44.09 221.51
2016-03-31 319.23 43.93 222.35
2015-12-31 299.97 43.77 229.60
2015-09-30 291.01 43.75 235.28
2015-06-30 150.78 84.72 133.61
2015-03-31 168.57 84.24 126.33
2014-12-31 -37.25 83.77 27.76
2014-09-30 -10.19 83.29 37.79
2014-06-30 1.07 82.81 43.44
2014-03-31 -35.39 31.28 5.04
2013-12-31 -19.67 0.00 6.13
2013-09-30 -9.58 0.01 16.37
2013-06-30 -8.46 0.01 0.29
  • Retrophin's level of debt (92.6%) compared to net worth is high (greater than 40%).
  • Retrophin had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Retrophin has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Retrophin has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Retrophin's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Retrophin has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Retrophin's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Retrophin dividends.
If you bought €2,000 of Retrophin shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Retrophin's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Retrophin's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:17R Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:17R Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Retrophin has not reported any payouts.
  • Unable to verify if Retrophin's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Retrophin's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Retrophin has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Retrophin's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Retrophin afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Retrophin has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Retrophin's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Eric Dube
AGE 46
TENURE AS CEO 1.3 years
CEO Bio

Dr. Eric Dube Ph.D. is Head of North America of ViiV Healthcare Limited. Dr. Dube serves as President and Chief Executive Officer at Retrophin, Inc since January 4, 2019 and its Director since January 2019. He has nearly 20 years of pharmaceutical leadership experience to head ViiV Healthcare’s operations in the US, Canada and Puerto Rico. His career at GSK in 2000 as a medical science liaison and has worked in a variety of marketing, sales, operations and strategy roles in the US, Japan and Europe. He served as vice president of managed markets for national accounts, as well as head of the oncology business unit where he oversaw multiple product launches and transformed the business model to better address emerging customer and patient needs. He then led commercial operations across the North America Pharma organization as senior vice president of strategy, planning and operations. In 2013, he joined GSK Japan as senior vice president and head of the 800-person respiratory business unit. Under his leadership, GSK Japan’s respiratory portfolio and business returned to growth. Most recently, as senior vice president and head of the global respiratory franchise, Eric established a 10-year strategic plan for the global respiratory portfolio focused on delivering sustained growth. During his tenure at GSK, he was the co-sponsor of the Women’s Leadership Initiative employee resource group and various diversity leadership development programs, and served on the Global LGBT+ Council. He currently represents ViiV Healthcare on the GSK US Race and Ethnicity Council. He has earned national and global recognition. He was on Fortune magazine’s “40 Under 40: Ones to Watch” list in 2011 and was named one of 2012’s “Emerging Pharma Leaders” by Pharmaceutical Executive. He was also featured on the Financial Times’ list of “OUTstanding 100 LGBT+ Executives” in 2018. His professional focus on addressing unmet needs of patients and customers has also influenced his personal interests. He served as a founding member of the board of directors for Puentes de Salud, a non-profit that promotes the health and wellness of Philadelphia’s Latino immigrant population. More recently, Eric joined the board of trustees for AIDS United, an organization committed to ending the AIDS epidemic in the US through strategic grantmaking, capacity building, and policy/advocacy. After graduating cum laude from Santa Clara University with a B.S. in Biopsychology, Eric earned an M.A. and Ph.D. in Psychology from Cornell University, where his studies focused on how culture, gender and ethnicity influenced resilience in the LGBTQ community. He also completed the Finance for Senior Executives program at Harvard Business School and studied four languages.

CEO Compensation
  • Insufficient data for Eric to compare compensation growth.
  • Insufficient data for Eric to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Retrophin management team in years:

2.1
Average Tenure
52
Average Age
  • The tenure for the Retrophin management team is about average.
Management Team

Laura Clague

TITLE
CFO & Senior VP
COMPENSATION
$2M
AGE
60
TENURE
5.4 yrs

Bill Rote

TITLE
Senior VP and Head of Research & Development
COMPENSATION
$2M
AGE
56
TENURE
3.3 yrs

Noah Rosenberg

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
52
TENURE
1.8 yrs

Eric Dube

TITLE
President
AGE
46
TENURE
1.3 yrs

Chris Cline

TITLE
Vice President of Investor Relations & Corporate Communications

Elizabeth Reed

TITLE
Senior VP
COMPENSATION
$2M
AGE
48
TENURE
3.3 yrs

Casey Logan

TITLE
Vice President of Corporate Development
TENURE
2.1 yrs

Peter Heerma

TITLE
Chief Commercial Officer
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the Retrophin board of directors in years:

3.9
Average Tenure
54
Average Age
  • The tenure for the Retrophin board of directors is about average.
Board of Directors

Gary Lyons

TITLE
Independent Chairman of the Board
COMPENSATION
$414K
AGE
68
TENURE
3.9 yrs

Eric Dube

TITLE
President
AGE
46
TENURE
1.3 yrs

Jeff Meckler

TITLE
Independent Director
COMPENSATION
$399K
AGE
52
TENURE
5.5 yrs

Tim Coughlin

TITLE
Independent Director
COMPENSATION
$404K
AGE
52
TENURE
5.1 yrs

John Orwin

TITLE
Independent Director
COMPENSATION
$392K
AGE
54
TENURE
3.1 yrs

Steve Aselage

TITLE
Director
COMPENSATION
$5M
AGE
68
TENURE
7.3 yrs

Roy Baynes

TITLE
Independent Director
COMPENSATION
$392K
AGE
64
TENURE
3.8 yrs

Alan Beggs

TITLE
Member of Scientific Advisory Board

Stuart Swiedler

TITLE
Member of Scientific Advisory Board
AGE
62

Ron Squarer

TITLE
Independent Director
COMPENSATION
$387K
AGE
52
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • Retrophin individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Mar 20 Sell Stephen Aselage Individual 05. Mar 20 05. Mar 20 -4,359 €13.73 €-59,843
09. Mar 20 Sell Noah Rosenberg Individual 05. Mar 20 05. Mar 20 -1,790 €13.73 €-24,574
29. Nov 19 Sell Stephen Aselage Individual 29. Nov 19 29. Nov 19 -5,000 €12.63 €-63,126
X
Management checks
We assess Retrophin's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Retrophin has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company’s product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Details
Name: Retrophin, Inc.
17R
Exchange: DB
Founded: 2011
$591,064,075
43,115,508
Website: http://www.retrophin.com
Address: Retrophin, Inc.
3721 Valley Centre Drive,
Suite 200,
San Diego,
California, 92130,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RTRX Common Stock Nasdaq Global Market US USD 18. Dec 2012
DB 17R Common Stock Deutsche Boerse AG DE EUR 18. Dec 2012
BRSE 17R Common Stock Berne Stock Exchange CH CHF 18. Dec 2012
Number of employees
Current staff
Staff numbers
221
Retrophin employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:58
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/02/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.